261 related articles for article (PubMed ID: 22081778)
1. No acquisition: a new ambition for HIV vaccine development?
Lakhashe SK; Silvestri G; Ruprecht RM
Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
[TBL] [Abstract][Full Text] [Related]
2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
3. Adjuvants: tailoring humoral immune responses.
McElrath MJ
Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
[TBL] [Abstract][Full Text] [Related]
4. New concepts in HIV-1 vaccine development.
Stephenson KE; D'Couto HT; Barouch DH
Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
[TBL] [Abstract][Full Text] [Related]
5. Is developing an HIV-1 vaccine possible?
Haynes BF; Liao HX; Tomaras GD
Curr Opin HIV AIDS; 2010 Sep; 5(5):362-7. PubMed ID: 20978375
[TBL] [Abstract][Full Text] [Related]
6. Advances in HIV-1 Vaccine Development.
Gao Y; McKay PF; Mann JFS
Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
[TBL] [Abstract][Full Text] [Related]
7. The design and evaluation of HIV-1 vaccines.
Saunders KO; Rudicell RS; Nabel GJ
AIDS; 2012 Jun; 26(10):1293-302. PubMed ID: 22706011
[TBL] [Abstract][Full Text] [Related]
8. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
9. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
[TBL] [Abstract][Full Text] [Related]
10. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
11. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Stephenson KE; Wagh K; Korber B; Barouch DH
Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
[TBL] [Abstract][Full Text] [Related]
12. [Advances in the Immunogenic Design of HIV-1 Vaccine].
Zhang X; Wang T; Yu X
Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
[TBL] [Abstract][Full Text] [Related]
13. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
Haut LH; Ertl HC
J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
[TBL] [Abstract][Full Text] [Related]
14. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
16. Current views on the potential for development of a HIV vaccine.
Cohen KW; Frahm N
Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
[TBL] [Abstract][Full Text] [Related]
17. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
Doran RC; Tatsuno GP; O'Rourke SM; Yu B; Alexander DL; Mesa KA; Berman PW
PLoS One; 2018; 13(4):e0196370. PubMed ID: 29689099
[TBL] [Abstract][Full Text] [Related]
18. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
O'Connell RJ; Kim JH; Excler JL
Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
[TBL] [Abstract][Full Text] [Related]
19. AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition.
Singh A; Permar S; Kollmann TR; Levy O; Marovich M; De Paris K
mSphere; 2019 Jul; 4(4):. PubMed ID: 31315966
[TBL] [Abstract][Full Text] [Related]
20. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]